Other Deal Trends 2026: Activity Surges 1271% in 6 Months

96 deals. That is how many transactions classified outside traditional modality buckets closed between February 24 and August 24, 2026 — up 1271% from just 7 in the prior six-month window. This is not a rounding error or a data artifact. The explosion in other deal trends 2026 reflects a structural shift: Big Pharma is hunting in categories — platform technologies, combination approaches, drug-device hybrids, novel biologics that defy neat classification — that the industry historically ignored or undervalued. The assets that don't fit legacy taxonomies are now commanding the biggest checks.

The Data — Other Deal Activity, Period over Period

Seven deals in six months is a backwater. Ninety-six is a full-blown market. The magnitude of this jump demands scrutiny — and the underlying drivers hold direct consequences for anyone negotiating other licensing 2026 terms right now.

What's Driving the Trend

Three forces converge to explain this surge, and none of them are temporary.

First, pipeline diversification pressure has reached a breaking point. The top 20 pharma companies face a combined $200B+ in revenue exposure from patent cliffs through 2030 (per Evaluate Pharma's 2026 consensus forecast). Traditional small molecule and monoclonal antibody licensing markets are picked over. BD teams are being pushed — by boards, by pipeline reviews, by competitive dynamics — into categories that sit outside conventional classification: gene-modified cell therapies that aren't quite CAR-T, radiopharmaceutical conjugates, microbiome-drug combinations, AI-designed molecules with novel mechanisms. These assets get bucketed as "other" because the taxonomy hasn't caught up with the science. The deal volume has.

Second, regulatory tailwinds are real. FDA's 2025 guidance updates on combination products, platform-based approvals, and accelerated pathways for novel modalities removed friction that previously made these assets harder to value and harder to license. The agency's willingness to accept adaptive trial designs for unconventional therapeutic categories has de-risked a class of assets that pharma BD teams historically avoided because the regulatory path was opaque. That opacity is clearing. Deal flow follows.

Third, capital markets are rewarding differentiation. Biotech companies with truly novel, hard-to-classify platforms are commanding premium valuations in 2026. Investors — both public and private — have soured on me-too assets in crowded spaces like PD-1 and GLP-1 followers. This pushes founders to build in white space, and it pushes acquirers to pay up for assets that offer genuine portfolio differentiation. The result: a surge in other licensing 2026 transactions that reflects a market pricing novelty at a premium. Check the Deal Benchmarks data — upfront-to-TDV ratios in this category are compressing, which signals buyer eagerness and competitive tension in diligence processes.

Notable Deals

The CSPC-AstraZeneca deal is the anchor transaction of this entire trend. A $1.2B upfront and $18.5B total deal value for a Chinese-origin asset licensed to a top-5 pharma — in a non-traditional modality category — would have been unthinkable two years ago. AstraZeneca is signaling that it views these novel platforms as core to its 2030+ growth strategy, not as speculative optionality. The fact that CSPC appears twice in the same week, with a second $1.77B TDV structure, suggests a broader platform relationship, not a one-off transaction.

Novo Nordisk's $2.4B TDV deal with Omeros on July 18 reinforces the thesis. Novo is not a company that overpays. Its willingness to commit this kind of total value to an asset classified outside mainstream modalities tells you that internal portfolio gap analyses at Copenhagen are pointing toward non-traditional therapeutic categories. The undisclosed upfront makes it harder to benchmark the risk-sharing structure, but the TDV alone places this in the top decile of 2026 licensing deals across all modalities.

BridgeBio's $105M upfront from Novartis is more conventional in structure but notable for the licensor profile. BridgeBio has built its reputation on genetic medicine platforms that don't slot cleanly into gene therapy, small molecule, or biologic categories. Novartis paying a nine-figure upfront for this kind of asset validates the platform-level value that other deal trends 2026 are increasingly recognizing.

The Amgen-BeiGene transaction, with undisclosed financial terms, is the deal to watch for follow-on disclosures. Given both companies' scale and the timing cluster with the other July transactions, this likely represents either a significant co-development arrangement or a geographic licensing play for a novel modality in the China-to-global corridor.

What This Means for BD Teams Right Now

If you are selling: This is unambiguously a seller's market for differentiated, hard-to-classify assets. The 1271% deal volume increase means buyer demand is outpacing supply of quality assets. You have leverage. Use it. Push for higher upfronts as a percentage of TDV — the CSPC-AZ deal shows that $1B+ upfronts are on the table for the right asset. Do not accept milestone-heavy, upfront-light structures unless the milestones are near-term and clinically de-risked. Run competitive diligence processes. Multiple buyers are circling the same assets in this space.

If you are buying: Speed kills you less than missing the deal entirely. The July 2026 cluster — five major transactions in six days — suggests that pharma BD teams are racing to lock up novel-category assets before competitors close them out. Waiting for more data or clearer regulatory signals is a losing strategy when 96 deals have already transacted. Your search-and-evaluate funnel needs to expand beyond traditional modality screens. If your CRM is filtering out assets because they don't fit standard categories, you are structurally disadvantaged in this market.

On deal structure: Upfront-to-TDV ratios are shifting. The CSPC-AZ deal at roughly 6.5% upfront-to-TDV is aggressive but reflects the massive milestone tail in novel modality deals where approval timelines are longer and regulatory pathways are less precedented. BD teams should model scenario-weighted milestone NPVs carefully — use the Ambrosia calculator to stress-test whether your proposed structure aligns with current market rates for comparable risk profiles. Option-based structures and co-development arrangements are gaining favor because they allow buyers to stage capital deployment against technical risk in categories where historical approval rates are sparse.

Benchmark your deal against current market rates using the Ambrosia calculator. In a market moving this fast, relying on comps from even six months ago means you are negotiating with outdated information.